Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Heteroditopic binding of magnetic resonance contrast agents for increased relaxivity.

Literature DB >> 21370351

Heteroditopic binding of magnetic resonance contrast agents for increased relaxivity.

Zhaoda Zhang¹, Andrew F Kolodziej, Matthew T Greenfield, Peter Caravan.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21370351 PMCID： PMC3184248 DOI： 10.1002/anie.201007689

Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN： 1433-7851 Impact factor: 15.336

× No keyword cloud information.

16 in total

Review 1. Challenges for molecular magnetic resonance imaging.

Authors: Enzo Terreno; Daniela Delli Castelli; Alessandra Viale; Silvio Aime
Journal: Chem Rev Date: 2010-05-12 Impact factor: 60.622

2. Large relaxivity enhancement of paramagnetic lipid nanoparticles by restricting the local motions of the Gd(III) chelates.

Authors: Filip Kielar; Lorenzo Tei; Enzo Terreno; Mauro Botta
Journal: J Am Chem Soc Date: 2010-06-16 Impact factor: 15.419

3. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents.

Authors: Zhaoda Zhang; Matthew T Greenfield; Marga Spiller; Thomas J McMurry; Randall B Lauffer; Peter Caravan
Journal: Angew Chem Int Ed Engl Date: 2005-10-21 Impact factor: 15.336

4. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.

Authors: Martin Rohrer; Hans Bauer; Jan Mintorovitch; Martin Requardt; Hanns-Joachim Weinmann
Journal: Invest Radiol Date: 2005-11 Impact factor: 6.016

Review 5. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.

Authors: Peter Caravan
Journal: Chem Soc Rev Date: 2006-05-03 Impact factor: 54.564

6. Effect of Peptide-Chelate Architecture on Metabolic Stability of Peptide-based MRI Contrast Agents.

Authors: Zhaoda Zhang; Andrew F Kolodziej; Jianfeng Qi; Shrikumar A Nair; Xifang Wang; April W Case; Matthew T Greenfield; Philip B Graham; Thomas J McMurry; Peter Caravan
Journal: New J Chem Date: 2010-02-12 Impact factor: 3.591

7. Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo.

Authors: Vardan Amirbekian; Juan Gilberto S Aguinaldo; Smbat Amirbekian; Fabien Hyafil; Esad Vucic; Marc Sirol; David B Weinreb; Soizic Le Greneur; Eric Lancelot; Claire Corot; Edward A Fisher; Zorina S Galis; Zahi A Fayad
Journal: Radiology Date: 2009-05 Impact factor: 11.105

8. Magnetic resonance molecular imaging of vascular cell adhesion molecule-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic imaging probe.

Authors: Carmen Burtea; Sophie Laurent; Marc Port; Eric Lancelot; Sébastien Ballet; Olivier Rousseaux; Gérard Toubeau; Luce Vander Elst; Claire Corot; Robert N Muller
Journal: J Med Chem Date: 2009-08-13 Impact factor: 7.446

9. EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.

Authors: Kirsten Overoye-Chan; Steffi Koerner; Richard J Looby; Andrew F Kolodziej; Stephan G Zech; Qing Deng; Jaclyn M Chasse; Thomas J McMurry; Peter Caravan
Journal: J Am Chem Soc Date: 2008-04-08 Impact factor: 15.419

10. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility.

Authors: Josef Vymazal; Elmar Spuentrup; Gerardo Cardenas-Molina; Andrea J Wiethoff; Michael G Hartmann; Peter Caravan; Edward C Parsons
Journal: Invest Radiol Date: 2009-11 Impact factor: 6.016

13 in total

Heteroditopic binding of magnetic resonance contrast agents for increased relaxivity.

Review 1. Challenges for molecular magnetic resonance imaging.

2. Large relaxivity enhancement of paramagnetic lipid nanoparticles by restricting the local motions of the Gd(III) chelates.

3. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents.

4. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.

Review 5. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.

6. Effect of Peptide-Chelate Architecture on Metabolic Stability of Peptide-based MRI Contrast Agents.

7. Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo.

8. Magnetic resonance molecular imaging of vascular cell adhesion molecule-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic imaging probe.

9. EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.

10. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility.

1. Fibrin specific peptides derived by phage display: characterization of peptides and conjugates for imaging.

Review 2. Lanthanide probes for bioresponsive imaging.

3. Structure - relaxivity relationships among targeted MR contrast agents.

Review 4. MR imaging probes: design and applications.

5. Probing the structure-relaxivity relationship of bis-hydrated Gd(DOTAla) derivatives.

6. Discrete bimodal probes for thrombus imaging.

7. Fibrin-targeted PET probes for the detection of thrombi.

8. Molecular imaging of fibrin in a breast cancer xenograft mouse model.

Review 9. The importance of water exchange rates in the design of responsive agents for MRI.

10. The evolution of fibrin-specific targeting strategies.